Mallinckrodt to Present at Jefferies London Healthcare Conference

MNKKQ 11.14.2024

SERA-AI Powered Highlights
Date of Upcoming Event:2024-11-19
Name of Upcoming Event:Jefferies London Healthcare Conference
Full Press ReleaseSEC FilingsOur MNKKQ Tweets

About Gravity Analytica

Recent News

    Recent Filings

    • 01.17.2025 - 4/A Statement of changes in beneficial ownership of securities
    • 12.05.2024 - 8-K Current report

    DUBLIN,Nov. 14, 2024/PRNewswire/ --Mallinckrodt plc, a global specialty pharmaceutical company, today announced thatSiggi Olafsson, President and Chief Executive Officer, will present atJefferies London Healthcare ConferenceonTuesday, November 19, 2024at9:30 a.m. GMT/4:30 a.m. ET.

    Mallinckrodt logo

    Individuals who cannot attend the meeting in person can find webcast information at:https://wsw.com/webcast/jeff315/mnk/1699320.A replay will also be available following the meeting.

    ABOUT MALLINCKRODT

    Mallinckrodt is a global business consisting of multiple wholly owned subsidiaries that develop, manufacture, market and distribute specialty pharmaceutical products and therapies. The Company's Specialty Brands reportable segment's areas of focus include autoimmune and rare diseases in specialty areas like neurology, rheumatology, hepatology, nephrology, pulmonology, ophthalmology and oncology; immunotherapy and neonatal respiratory critical care therapies; analgesics; and gastrointestinal products. Its Specialty Generics reportable segment includes specialty generic drugs and active pharmaceutical ingredients. To learn more about Mallinckrodt, visitwww.mallinckrodt.com.

    Mallinckrodt uses its website as a channel of distribution of important company information, such as press releases, investor presentations and other financial information. It also uses its website to expedite public access to time-critical information regarding the Company in advance of or in lieu of distributing a press release or a filing with theSECdisclosing the same information. Therefore, investors should look to the Investor Relations page of the website for important and time-critical information. Visitors to the website can also register to receive automatic e-mail and other notifications alerting them when new information is made available on the Investor Relations page of the website.

    CONTACTS

    Investor RelationsDerek BelzVice President, Investor Relations314-654-3950derek.belz@mnk.com

    MediaMichael Freitag / Aaron Palash / Aura Reinhard /Catherine SimonJoele Frank, Wilkinson Brimmer Katcher212-355-4449

    Mallinckrodt, the "M" brand mark and theMallinckrodt Pharmaceuticalslogo are trademarks of a Mallinckrodt company. Other brands are trademarks of a Mallinckrodt company or their respective owners. © 2024.

    CisionView original content to download multimedia:https://www.prnewswire.com/news-releases/mallinckrodt-to-present-at-jefferies-london-healthcare-conference-302305741.html

    SOURCE Mallinckrodt plc

    Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com